Clinical trials
Chronic Hepatitis clinical trials
Below are recruiting chronic hepatitis clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03097952Recruiting
Study of people with long-term hepatitis B in real life
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
Changzhou, JiangsuAges Any age - NCT05335603Recruiting
Study of adults with liver conditions linked to fatty liver
This study looks at adults with different long-term liver conditions that are associated with fatty liver. It helps researchers better understand these diseases and factors linked to them.
HvidovreAges 18 years+ - NCT06047093Recruiting
Study of Hepatitis B Virus in the Liver
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
LyonAges 18 years+ - NCT07540637Recruiting
Study of how well patients take hepatitis B medication with app support
This study tests whether a smartphone app called HBVCare helps patients with chronic hepatitis B stick to their treatment plans. Researchers will track how well the app helps patients take their medicines on time and understand what makes treatment adherence easier or harder.
HanoiAges 18 years+ - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT07499544RecruitingPhase 3
Testing Libevitug for chronic hepatitis D
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Garden Grove, CaliforniaAges 12–70 - NCT06779864Recruiting
Hepatitis B virus genetics and drug resistance study
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07137247Recruiting
How the immune system changes over time in chronic hepatitis B
This study tracks how the immune system works in people with chronic hepatitis B who haven't taken antiviral medication in the last 6 months. It aims to understand the natural history of the infection without treatment.
Guangzhou, GuangdongAges 1–80 - NCT06122285Recruiting
Bulevirtide for chronic hepatitis delta
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
Milan, MIAges 18 years+ - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT03200379Recruiting
Taiwan registry for people treated for hepatitis C
This registry is for people in Taiwan who have received direct-acting antiviral (DAA) treatment for hepatitis C. It collects health information to better understand outcomes and care, and you can join if you agree to participate and sign consent.
Kaohsiung CityAges Any age - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT07454837RecruitingPhase 2/Phase 3
Switching to brelovitug for chronic hepatitis D patients on bulevirtide
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
GrazAges 18 years+ - NCT07771140RecruitingPhase 1
Study of an experimental injection for chronic hepatitis b
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
HefeiAges 18–65 - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05597488Recruiting
Measuring pressure to predict varice treatment response
This study checks whether a special ultrasound-guided measurement of blood pressure in your liver can help predict how well endoscopic treatment (banding varices or injecting bleeding sites) will work. It aims to improve outcomes by identifying who is more likely to respond.
Hong Kong, Hong KongAges 18–75 - NCT05583006Recruiting
Switch from entecavir to tenofovir for chronic hepatitis B
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Taichung, TaiwanAges 20 years+ - NCT07600788RecruitingPhase 1
Liver Function and Safety Study of AHB-137 Injection
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT04446832Recruiting
Vaccine study for people waiting for liver transplant
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
LyonAges 18 years+ - NCT05661786Recruiting
Study outcomes for hepatitis B with “indeterminate” disease phase
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Changzhou, JiangsuAges 18 years+
Hear when a new Chronic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis?
- Yes. Clin2 currently lists 134 recruiting chronic hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.